Taysha Gene Therapies, Inc. (TSHA)
TSHANASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$4.37
+0.0400 (+0.92%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $1.42bn
- P/E
- –
- EPS, last 4 quarters
- $-0.4200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.46 to $7.30
- Average volume
- 3.84m
- Previous close
- $4.33
Analysts
7 coveringBuy7 buy, 0 hold, 0 sell
Targets a year out average $14.00, +220.4% from here
Earnings
next estimate $-0.1400Next report Nov 12, 2026
Sep 2025
0.0%
Dec 2025
+27.3%
Mar 2026
-20.0%
Jun 2026
-18.2%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | $5.49m | – | – |
| Gross profit | – | $5.49m | – | – |
| Operating income | -$34.02m | -$28.30m | -$43.49m | -$47.35m |
| Net income | -$32.73m | -$27.85m | -$42.41m | -$46.64m |
News
8 latest- These 3 Risky Stocks Could Be Sitting on 100% UpsideMarketBeat · Sep 7, 2026
- Taysha Gene Therapies (TSHA) Q2 2026 Earnings CallThe Motley Fool · Aug 18, 2026
- Taysha Gene Therapies Q2 Earnings Call HighlightsMarketBeat · Aug 11, 2026
- Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% RunThe Motley Fool · Jul 12, 2026
- Taysha Gene Therapies Prices Approx. $200 Mln Offering Of Shares And Warrants; Stock Down RTTNews · Jun 25, 2026
- Taysha (TSHA) Q1 2026 Earnings TranscriptThe Motley Fool · May 7, 2026
- Taysha To Present Preclinical Data On TSHA-102 Gene Therapy In Treatment Of Rett Syndrome RTTNews · Apr 28, 2026
- Taysha (TSHA) Q4 2025 Earnings Call TranscriptThe Motley Fool · Mar 19, 2026
The company
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company's management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- tayshagtx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.